Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: This study aimed to examine the degradation of tigecycline in Mueller Hinton broth (ca-MHB), as knowledge about bacterial susceptibility is key for therapeutic decisions.
Methods: Antioxidative stabilizers were evaluated on tigecycline stability in a quantitative chromatography assay and tigecycline induced kill against Staphylococcus aureus (ATCC29213) was determined in time kill studies.
Results: Ascorbic acid caused rapid degradation of tigecycline and resulted in loss of antibacterial activity. Tigecycline was stabilized in aged broth by 2% pyruvate and bacterial growth, and tigecycline killing was similar to fresh broth without supplementation, but independent of age.
Conclusion: Our results underline the importance of using freshly prepared ca-MHB or the need for stabilizers for tigecycline susceptibility testing while using aged ca-MHB.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782409 | PMC |
| http://dx.doi.org/10.1007/s10096-020-03970-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Efficacy and Safety of Omadacycline Versus Tigecycline in Treating Severe Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacilli: A Retrospective Cohort Study.
Infect Drug Resist
September 2025
Department of Intensive Care Unit, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
Objective: To investigate the clinical efficacy and safety of intravenous omadacycline compared to intravenous tigecycline in patients with severe pneumonia caused by carbapenem-resistant gram-negative bacilli (CRGNB), and to explore the factors influencing 28-day all-cause mortality.
Methods: Our retrospective analysis was conducted on adult patients with CRGNB-associated severe pneumonia who received intravenous omadacycline or tigecycline for at least 72 hours in the intensive care unit (ICU) between April 1, 2023, and March 31, 2025. The primary outcome was 28-day all-cause mortality, while secondary endpoints included clinical efficacy and microbiological clearance rates.
Hypervirulent Carbapenem-resistant Infection: Epidemiology, Virulence, Resistance, and Treatment.
Infect Drug Resist
September 2025
Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, Jilin, 130000, People's Republic of China.
In recent years, reports of hypervirulent (hv) carbapenem-resistant (CR) (Kp) (hv-CRKp) have gradually increased. hv-CRKp may emerge from hvKp acquiring mobile genetic elements carrying multiple antibiotic-resistance genes or multi-drug-resistant Kp acquiring virulence genes, with subsequent convergence of resistance and virulence. Thus, hv-CRKp simultaneously harbors resistance and virulence genes and may even show resistance to colistin and tigecycline, suggesting potential for causing severe infections and placing a serious burden on the health care system.
View Article and Find Full Text PDFEtiological Profiles and Antibiotic Resistance of Urinary Tract Infections Among Different Age Categories in Children: A Retrospective Study of Xiamen Single-Center.
Infect Drug Resist
September 2025
Department of Nephrology, Children's Hospital of Fudan University, Shanghai, People's Republic of China.
Purpose: To analyze the distribution of pathogens and drug resistance in children with urinary tract infections (UTIs) in a single center in Xiamen and to guide the selection of empirical antibiotics in the clinic.
Methods: Clinical data of 2001 children with UTIs in Xiamen Children's Hospital between 2014 and 2022 were retrospectively analyzed, grouped by age and comorbidities. Differences in pathogen distribution and drug sensitivity were compared with the chi-square test applied and significance set at p < 0.
A Randomized, Observer-Blinded, Active-Controlled, Phase IIIb Study to Compare IV/Oral Delafloxacin Fixed-Dose Monotherapy With Best Available Treatments in a Microbiologically Enriched Population With Surgical Site Infections: The DRESS Study.
Open Forum Infect Dis
September 2025
Faculty of Medicine and Surgery, Catholic University of Sacred Heart, Rome, Italy.
Background: Surgical site infections (SSIs) are the most common skin and skin structure infections and are mostly polymicrobial, requiring hospitalization and broad-spectrum antibiotics. This clinical trial evaluated the noninferiority of delafloxacin vs best available therapy (BAT) for the treatment of superficial or deep incisional SSI following a cardiothoracic/related leg or abdominal surgical procedure.
Methods: In this randomized, observer-blinded, active-controlled, parallel-group, multicenter, phase IIIb study, patients with SSI were randomized 1:1 to receive delafloxacin 300 mg intravenous (IV)/450 mg oral (OS) or BAT IV/OS (vancomycin or linezolid for cardiothoracic SSI, piperacillin/tazobactam or tigecycline for abdominal SSI).
Determining minimal inhibitory concentrations and antibiotic susceptibility for Enterobacterales by flow cytometry using reactive oxygen species as a marker.
PLoS One
September 2025
Division of Pharmacy, Singapore General Hospital, Singapore.
Early appropriate antibiotic treatment is vital in reducing patient mortality. However, current antimicrobial susceptibility testing (AST) requires 16-24 hours of incubation, delaying appropriate antibiotic treatment. Flow cytometry (FCM) is a rapid method in assessing fluorescence (such as fluorophores for ROS) at single-cell resolution.
View Article and Find Full Text PDF